To overcome stability and heterogeneity
issues of antibody–drug
conjugates (ADCs) produced with existing bioconjugation technologies
incorporating a maleimide motif, we developed McSAF Inside, a new
technology based on a trifunctionalized di(bromomethyl)pyridine scaffold.
Our solution allows the conjugation of a linker-payload to previously
reduced interchain cysteines of a native antibody, resulting in disulfide
rebridging. This leads to highly stable and homogeneous ADCs with
control over the drug-to-antibody ratio (DAR) and the linker-payload
position. Using our technology, we synthesized an ADC, MF-BTX-MMAE, built from anti-CD30 antibody cAC10 (brentuximab), and compared
it to Adcetris, the first line treatment against CD30-positive lymphoma,
in a CD30-positive lymphoma model. MF-BTX-MMAE displayed
improved DAR homogeneity, with a solid batch-to-batch reproducibility,
as well as enhanced stability in thermal stress conditions or in the
presence of a free thiol-containing protein, such as human serum albumin
(HSA). MF-BTX-MMAE showed antigen-binding, in
vitro cytotoxicity, in vivo efficacy, and
tolerability similar to Adcetris. Therefore, in accordance with current
regulatory expectations for the development of new ADCs, McSAF Inside
technology gives access to relevant ADCs with improved characteristics
and stability.